Standard
Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide? / Foghsgaard, S.; Vedtofte, L.; Bahne, E.; Andreasen, C.; Christiansen, L. K.; Svare, J. A.; Clausen, T. D.; Mathiesen, E. R.; Damm, P.; Gluud, L. L.; Knop, F. K.; Vilsboll, T.
In:
Diabetologia, Vol. 60, No. S1, 2017, p. S369-S369.
Research output: Contribution to journal › Conference abstract in journal › Research
Harvard
Foghsgaard, S, Vedtofte, L, Bahne, E, Andreasen, C, Christiansen, LK, Svare, JA
, Clausen, TD, Mathiesen, ER, Damm, P, Gluud, LL, Knop, FK & Vilsboll, T 2017, '
Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide?',
Diabetologia, vol. 60, no. S1, pp. S369-S369.
https://doi.org/10.1007/s00125-017-4350-zAPA
Foghsgaard, S., Vedtofte, L., Bahne, E., Andreasen, C., Christiansen, L. K., Svare, J. A.
, Clausen, T. D., Mathiesen, E. R., Damm, P., Gluud, L. L., Knop, F. K., & Vilsboll, T. (2017).
Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide? Diabetologia,
60(S1), S369-S369.
https://doi.org/10.1007/s00125-017-4350-zVancouver
Foghsgaard S, Vedtofte L, Bahne E, Andreasen C, Christiansen LK, Svare JA et al.
Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide? Diabetologia. 2017;60(S1):S369-S369.
https://doi.org/10.1007/s00125-017-4350-zAuthor
Foghsgaard, S. ; Vedtofte, L. ; Bahne, E. ; Andreasen, C. ; Christiansen, L. K. ; Svare, J. A. ; Clausen, T. D. ; Mathiesen, E. R. ; Damm, P. ; Gluud, L. L. ; Knop, F. K. ; Vilsboll, T. / Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide?. In: Diabetologia. 2017 ; Vol. 60, No. S1. pp. S369-S369.
Bibtex
@article{9d8209793bb848ae81db5e7c444931a0,
title = "Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide?",
author = "S. Foghsgaard and L. Vedtofte and E. Bahne and C. Andreasen and Christiansen, {L. K.} and Svare, {J. A.} and Clausen, {T. D.} and Mathiesen, {E. R.} and P. Damm and Gluud, {L. L.} and Knop, {F. K.} and T. Vilsboll",
year = "2017",
doi = "10.1007/s00125-017-4350-z",
language = "English",
volume = "60",
pages = "S369--S369",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer",
number = "S1",
}
RIS
TY - ABST
T1 - Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide?
AU - Foghsgaard, S.
AU - Vedtofte, L.
AU - Bahne, E.
AU - Andreasen, C.
AU - Christiansen, L. K.
AU - Svare, J. A.
AU - Clausen, T. D.
AU - Mathiesen, E. R.
AU - Damm, P.
AU - Gluud, L. L.
AU - Knop, F. K.
AU - Vilsboll, T.
PY - 2017
Y1 - 2017
U2 - 10.1007/s00125-017-4350-z
DO - 10.1007/s00125-017-4350-z
M3 - Conference abstract in journal
VL - 60
SP - S369-S369
JO - Diabetologia
JF - Diabetologia
SN - 0012-186X
IS - S1
ER -
